companies developing glp 1 drugs Solving the Unmet Needs in Obesity Treatment | Obesity Pulse GLP-1 Receptor Agonist Market Size

There may be risk of cardiac arrhythmias

Evidence-based lifestyle interventionsincluding structured dietary advice, physical activity programmes, and psychological supportshould be explored as first-line approaches

Glucagon-like peptide-1 (GLP-1) receptor agonist and dual agonist therapies are FDA-approved for the treatment of obesity, weight management, type 2 diabetes mellitus and cardiovascular mortality reduction

Source: West, S et al Weight regain after cessation of medication for weight management: systematic review and meta-analysis, BMJ January, 2026 Newer incretin mimetics are the GLP-1 medications semaglutide and tirzepatide

The new move comes as Eli Lilly has also taken action against compounders making copies of tirzepatide, its GLP-1 and GIP agonist sold as Mounjaro for diabetes and Zepbound for obesity in the US

Its not healthy